Abstract library

284 results for "new service".
#2811 Improving Diagnosis Times as Part of the Transformation of the South Wales NET Service
Introduction: Transformation of the South Wales NET service in late 2017 introduced new specialised staff, gastroenterology-led clinics and improved MDTs with a particular emphasis on educating referring specialties. This has led to improved overall patient experience, satisfaction and quality of life. NETs are recognised world-wide for their lengthy diagnosis times.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Kapish Amin
#2932 Evaluation of Nurse Preferences between the Lanreotide Autogel New Syringe and Octreotide Long-Acting Release Syringe: An International Simulated Use Study (PRESTO)
Introduction: A new lanreotide autogel/depot (LAN) syringe was developed based on feedback from a human factors study to improve user experience.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Xuan Mai Truong Thanh
#3021 Homecare Service for Administration of Lanreotide Autogel Injections: Assessment of Patients’ Experience
Introduction: In the past, all Neuroendocrine Neoplasm (NEN) patients (pts) on long-acting somatostatin analogues (SA), had to attend local hospitals/clinics to have them administered by nurses/doctors. Recently, a “homecare service” was developed, allowing pts to have their injections delivered to their home and injections were either administered by themselves, their partner or a Specialist Nurse (SN).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Julian Gertner
Keywords: homecare
#2802 EvAluation de Satisfaction Infirmière (Nurse Satisfaction Evaluation). Observational Study of the Preparation and Intramuscular Administration of the Previous and New Long-Acting Release Octreotide LAR Formulation (EASI)
Introduction: A new formulation of octreotide LAR (OCT LAR) with a new diluent has been developed to facilitate the preparation and administration.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Alexandre Santos
#469 Cost-Effectiveness of Sunitinib in Patients with Advanced or Metastatic Pancreatic Neuroendocrine Tumors in Portugal
Introduction: Sunitinib is an oral multitargeted tyrosine kinase inhibitor approved in Europe in 2010 for use in well-differentiated pancreatic neuroendocrine tumors (pNET) that have spread or cannot be removed by surgery.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Mónica Inês
Authors: Soares M, Inês M, Contente M, ...
#1491 Do Medical Oncology Services Receive More Patients with Neuroendocrine Tumors? Assessment of This Tendency and Reflections About Its Aid Complexity
Introduction: Neuroendocrine tumors meant a change in the clinical practice, multidisciplinary approach (MA) is the gold standard today.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Carmen Salvador
#1896 Launching NETwerk: Diagnosis and Treatment of Neuroendocrine Tumors within a Multi-Institutional Collaboration in the Region of Antwerp-Waasland in Belgium
Introduction: Centralizing cancer services is one way to improve global outcome for cancer patients but brings along that patients must be motivated to travel and that doctors of local hospitals get deprived of the diagnostic and treatment skills. The alternative way is to centrally coordinate cancer services across different hospitals. In this scenario, local multidisciplinary teams refer all patients to be discussed among cancer specialists. This continuous feed-back system also creates the opportunity to propose additional more specific and sensitive examinations for individual patients which would introduce the end of local substandard treatment.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Prof. Marc Peeters
#2130 Remote Tracking of Symptoms, QoL and Wellbeing within the New Wales NET Service
Introduction: Patients with NETs have worse health-related quality of life (HRQoL) than the general population.
Technological advances have significantly increased electronic patient-reported outcome (ePRO) data collection capabilities.
There is little longitudinal PRO/ePRO data and limited data on gastrointestinal symptoms, particularly ‘diarrhoea’, in NET patients.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Mark Reynolds
#2195 Audit of a New Nurse-Led Non-Medical Prescribing (NMP) Clinic for Systemic Anti-Cancer Agents (SACTs)
Introduction: The number of people living with cancer in the UK continues to rise with increased demands on specialist cancer care services. NET incidence and prevalence increases alongside this demand. NETs remain a rare cancer with specialist needs. The clinical nurse specialist (CNS) is ideally placed to support these patients. Oncology clinics are increasingly pressured, the need to think of innovative ways of reducing strain whilst maintaining and enhancing the patients experience is important. To address this we set up a nurse-led SACT NMP clinic alongside the oncology clinic to improve patient experience and reduce oncologist clinic review.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Philippa Davies
#2703 Carcinoid Heart Disease: A Retrospective Study and a Multidisciplinary Proposal of a New Algorithm
Introduction: Development of carcinoid heart disease (CHD) is the major negative prognostic factor in patients with the carcinoid syndrome. The only effective treatment is valve replacement. However, the selection of candidates and determination of optimal timing remain unclear. Considerable variability in local treatment strategies exist
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Aicha Bengueddach